MicroRNA-135a Expression is Upregulated in Hepatocellular Carcinoma and Targets Long Non-coding RNA TONSL-AS1 to Suppress Cell Proliferation

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Oct 11

PMID 34630715

Citations 2

Authors

Xuesong Deng

Jun Cheng

Naiyang Zhan

Jianwei Chen

Yongqiang Zhan

Yong Ni

Caixian Liao

Affiliations

Soon will be listed here.

Abstract

Dysregulation of long non-coding RNAs (lncRNAs) results in development of human diseases, including hepatocellular carcinoma (HCC). lncRNA TONSL-AS1 has been reported to act as a tumor suppressor in gastric cancer. The present study aimed to investigate the role of TONSL-AS1 in hepatocellular carcinoma (HCC). Reverse transcription-quantitative PCR analysis was performed to detect the expression levels of TONSL-AS1 and microRNA (miRNA/miR)-135a in HCC tissues and paired adjacent normal tissues. A 5-year follow-up study was performed to determine the prognostic value of TONSL-AS1 in HCC. The association between miR-135a and TONSL-AS1 was assessed via overexpression experiments. The Cell Counting Kit-8 assay was performed to assess cell proliferation. The results demonstrated that TONSL-AS1 expression was downregulated in HCC tissues, which was associated with a lower survival rate in patients with HCC. TONSL-AS1 and miR-135a were predicted to interact with each other, whereby overexpression of miR-135a downregulated TONSL-AS1 expression. The results demonstrated that TONSL-AS1 and miR-135a were inversely correlated with each other. Notably, overexpression of TONSL-AS1 inhibited HCC cell proliferation, while overexpression of miR-135a promoted HCC cell proliferation and decreased the effect of overexpression of TONSL-AS1 on cell proliferation. Taken together, the results of the present study suggest that miR-135a expression is upregulated in HCC and targets lncRNA TONSL-AS1 to suppress cell proliferation.

Citing Articles

The Role MicroRNA-135a in Suppressing Tumor Growth in Kidney Cancer Through the Regulation of Phosphoprotein Phosphatase2A and the Activation of the AKT and ERK1/2 Signaling Pathways.

Wang K, Chen H, Chen X, Fang Z, Xiao E, Liao Q J Cancer. 2024; 15(4):999-1008.

PMID: 38230208 PMC: 10788712. DOI: 10.7150/jca.90756.

inhibits the proliferation of HBV-infected hepatocellular carcinoma cells by targeting .

Lin J, Lian X, Xue S, Ouyang L, Zhou L, Lu Y Transl Cancer Res. 2023; 12(1):135-149.

PMID: 36760373 PMC: 9906062. DOI: 10.21037/tcr-22-2789.

References

Saran U, Humar B, Kolly P, Dufour J . Hepatocellular carcinoma and lifestyles. J Hepatol. 2015; 64(1):203-14. DOI: 10.1016/j.jhep.2015.08.028. View

Lang N, Wang C, Zhao J, Shi F, Wu T, Cao H . Long non‑coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR‑149/PKM2 axis in non‑small‑cell lung cancer. Mol Med Rep. 2020; 21(3):1509-1516. PMC: 7003037. DOI: 10.3892/mmr.2020.10944. View

Lu T, Seto W, Zhu R, Lai C, Yuen M . Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol. 2014; 19(47):8887-94. PMC: 3870540. DOI: 10.3748/wjg.v19.i47.8887. View

Wang J, Yang J, Zhang H, Liao Y, Xu D, Ma S . Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells. Oncol Lett. 2020; 20(1):914-920. PMC: 7286134. DOI: 10.3892/ol.2020.11598. View

Sawey E, Chanrion M, Cai C, Wu G, Zhang J, Zender L . Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011; 19(3):347-58. PMC: 3061399. DOI: 10.1016/j.ccr.2011.01.040. View

Tarocchi M, Polvani S, Marroncini G, Galli A . Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014; 20(33):11630-40. PMC: 4155355. DOI: 10.3748/wjg.v20.i33.11630. View

Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M . Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017; 67(2):302-309. DOI: 10.1016/j.jhep.2017.03.011. View

Li C, Chen Y . Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013; 45(8):1895-910. DOI: 10.1016/j.biocel.2013.05.030. View

Xie Y, Li F, Li Z, Shi Z . miR-135a suppresses migration of gastric cancer cells by targeting TRAF5-mediated NF-κB activation. Onco Targets Ther. 2019; 12:975-984. PMC: 6362934. DOI: 10.2147/OTT.S189976. View

10.

Yang C, Zheng X, Ye K, Sun Y, Lu Y, Fan Q . miR-135a Inhibits the Invasion and Migration of Esophageal Cancer Stem Cells through the Hedgehog Signaling Pathway by Targeting Smo. Mol Ther Nucleic Acids. 2020; 19:841-852. PMC: 6976902. DOI: 10.1016/j.omtn.2019.10.037. View

11.

Wang P, Yang X, Zhao L, Liu D, Liu J, Ding Y . A novel long non-coding RNA TONSL-AS1 regulates progression of gastric cancer via activating TONSL. Exp Cell Res. 2019; 382(1):111453. DOI: 10.1016/j.yexcr.2019.05.034. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen S . lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. Mol Oncol. 2019; 13(10):2246-2258. PMC: 6763783. DOI: 10.1002/1878-0261.12553. View

14.

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

15.

Hiotis S, Rahbari N, Villanueva G, Klegar E, Luan W, Wang Q . Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012; 12:64. PMC: 3407024. DOI: 10.1186/1471-230X-12-64. View

16.

Altekruse S, Henley S, Cucinelli J, McGlynn K . Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542-53. PMC: 4148914. DOI: 10.1038/ajg.2014.11. View

17.

Marra M, Sordelli I, Lombardi A, Lamberti M, Tarantino L, Giudice A . Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011; 9:171. PMC: 3213217. DOI: 10.1186/1479-5876-9-171. View

18.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

19.

Mao X, Zhang L, Huang B, Zhou S, Liao J, Chen L . Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med. 2015; 13:86. PMC: 4367980. DOI: 10.1186/s12967-015-0438-8. View

20.

Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y . miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012; 12:111. PMC: 3350382. DOI: 10.1186/1471-2407-12-111. View